Drug Trial Radar · NCT07929740
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Feb 28, 2029
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- Kura Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the pharmacokinetics (PK) of ziftomenib drug products to inform relative bioavailability (rBA) and bioequivalence (BE) assessments.
Conditions
- Myelodysplastic Syndrome (MDS)/AML
- Myeloid Leukemia, Acute
Interventions
ZiftomenibDrug
Oral Formulation 1
ZiftomenibDrug
Oral Formulation 2
ZiftomenibDrug
Oral Formulation 3
ZiftomenibDrug
Oral Formulation 4
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C)Time frame: During the first 56 days of ziftomenib
- To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B)Time frame: During the first 56 days of ziftomenib
- To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C)Time frame: During the first 56 days of ziftomenib
- To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B)Time frame: During the first 56 days of ziftomenib
- To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B)Time frame: During the first 56 days of ziftomenib
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.